May 17, 2023 02:20 PM EDT
FDA+

Mer­ck de­fends an­tibi­otic's ap­proval from 2019 as BMJ in­ves­ti­ga­tion points to 'de­cline' in FDA stan­dards

Zachary Brennan

Senior Editor

A new BMJ in­ves­ti­ga­tion and com­pan­ion ed­i­to­r­i­al pub­lished ear­li­er this week is rais­ing ques­tions on if the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mod­er­na re­ports slow start to RSV sales as Ban­cel steps back from com­mer­cial role

Sarep­ta dis­con­tin­ues work on next-gen ex­on-skip­ping drug for Duchenne

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

Q&A: Demis Has­s­abis talks win­ning the No­bel Prize, build­ing an AI biotech sans lab, and Trump’s po­ten­tial im­pact

GSK CEO Em­ma Walm­s­ley on the new Trump ad­min­is­tra­tion, trust, AI and Chi­na

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times